LabCentral 238 has secured $12.5m from founding sponsor Astellas, which will also provide capital for LabCentral's existing incubator.

Pharmaceutical firm Astellas has committed $12.5m to become the founding sponsor of a biotech incubator that will be launched by US-based laboratory space provider and startup hub LabCentral. The new hub, dubbed LabCentral 238, will be located in Cambridge, Massachusetts and will also be supported by a $5m grant from public-private economic development and investment…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.